Medvi vs. Zepbound: What You're Really Choosing Between

What you're actually comparing: Medvi's compounded catalog vs. Zepbound's FDA-approved shot

Medvi's marketing leans hard on the tablet — a dissolvable tirzepatide pill, no needle, mailed to your door. What often gets left out is that Medvi also compounds tirzepatide as a weekly injection, alongside compounded semaglutide in both formats, and even brokers access to brand-name Zepbound and Wegovy through a separate membership plan. Zepbound has exactly one format: an injection, either a single-dose vial or a prefilled KwikPen, reviewed and approved by the FDA as a finished drug in 2023. The real comparison isn't pill versus shot — it's an FDA-approved injectable brand against a compounding pharmacy's broader menu of the same active molecule.

That distinction carries real weight. A compounded product, oral or injected, is prepared by a licensed pharmacy under an individual prescription rather than manufactured and reviewed as a finished drug the way Zepbound was. Both can be legitimate medications with real clinical oversight behind them — they sit in different regulatory categories, and that difference is where most of this page's honest caveats live.

Is Medvi legit and safe compared to Zepbound?

Medvi is a genuine telehealth operation, not a storefront selling an unregulated supplement — it runs a real medical intake, uses licensed prescribers, and dispenses through a licensed compounding pharmacy network. It's also a company the FDA has already flagged once: on February 20, 2026, the agency sent Medvi a warning letter over website language claiming its compounded products share "the same active ingredient as" Wegovy, Ozempic, Mounjaro, and Zepbound — phrasing the FDA said implies an equivalence and approval status the compounded versions don't have. Medvi wasn't singled out; more than 30 telehealth companies received a similar letter the following month. Reputation-wise, the read is mixed rather than damning — solid on Trustpilot, rougher on ConsumerAffairs, mainly over billing complaints. Zepbound carries none of this baggage, simply because it isn't a compounding operation: it's a drug manufactured by Eli Lilly with an FDA approval that's already been through the review Medvi's product hasn't.

None of that makes Medvi a scam — a legitimate telehealth pathway and an FDA-approved finished drug are two different, both-real things. For the fuller line-by-line audit, including pharmacy sourcing, exact reputation scores, and state coverage detail, see the deeper tirzepatide pills and patches legitimacy check.

Medvi vs. Zepbound: the real price face-off

Line the two up by what you'd actually pay, not the headline number in either company's ad, and the gap narrows considerably. Medvi's first month is the figure that shows up in most ads — around $279, whichever format you choose. What happens after that first month is where sources genuinely disagree: some report a flat $399 a month regardless of dose, others describe a ladder climbing toward $449 to $499 at higher doses. Confirm your specific number in writing before your first refill, because the discount month isn't the number to budget against.

Zepbound's LillyDirect self-pay price is more consistent across sources than Medvi's (see the table above for the exact tiers), and it comes with one real catch: miss the 45-day refill window and the price resets much higher. At the entry tier, Medvi's discounted first month undercuts Zepbound; at the maintenance doses most people land on, the two are often within $50 of each other.

Skip either self-pay program and Zepbound's retail price is a different conversation entirely — a GoodRx coupon commonly lands around $995 to $1,090 a month with no LillyDirect discount applied, and full retail with no program at all runs even higher. For the complete cost ladder across every access path, including insurance and the savings card, see Zepbound cost.

Pill, injection, or both — Medvi's format menu is wider than the ads suggest

If you came in assuming this is a pill-versus-shot decision, it's worth resetting that expectation. Medvi compounds tirzepatide as both a daily dissolving tablet and a weekly injection, so choosing Medvi doesn't automatically mean choosing the needle-free route — that's a second decision inside Medvi's own menu. Zepbound, by contrast, has no pill option at all: it's injection-only, vial or KwikPen, because tirzepatide is a peptide that doesn't survive digestion intact without specialized formulation work nobody has published for a compounded oral version.

So the real format question splits in two. Between Medvi and Zepbound, the choice is brand-name FDA review versus a compounding pharmacy's broader catalog. Within Medvi, the choice is tablet versus injection, and that second decision carries its own asterisk — the injection is mechanically closer to Zepbound, sharing the same delivery route the approved drug uses, while the tablet is the format still missing published human absorption data. If avoiding needles is the whole reason you're looking at Medvi, know you'd be choosing the less-studied of Medvi's own two formats, not just a cheaper alternative to the shot.

Is Medvi's compounded tirzepatide the same drug, as effective as Zepbound?

Same active molecule, different regulatory story. Medvi's compounded tirzepatide — tablet or injection — is mixed by a pharmacy under an individual prescription rather than manufactured and reviewed as a finished product the way Zepbound was. That means no independent FDA verification of batch-to-batch consistency or sterility for Medvi's specific product, in either format. The injectable version at least travels the same route into your bloodstream that Zepbound uses, so its basic mechanism isn't in question the way the tablet's is — but neither format carries the kind of published human data behind Zepbound's own clinical trials. That's not the same as saying either one doesn't work; it means the evidence available for each is genuinely different, not that one is proven and the other isn't.

Is compounded tirzepatide from Medvi still legal right now?

Yes, on the narrower 503A basis that survived after the FDA declared the tirzepatide shortage resolved in December 2024 and phased out broad 503B compounding — a licensed pharmacy compounding for one named patient with a documented clinical reason, not cost alone. That status is still worth rechecking rather than assuming fixed: a further FDA proposal to remove tirzepatide from 503B bulk compounding remains open for comment as of this writing. Tirzepatide vs. Zepbound covers the full 503A/503B legal picture in more depth than fits here.

Does insurance or a savings card work with either?

Not with Medvi, structurally. Compounded medication is cash-pay by definition — there's no insurance billing code and no manufacturer savings card that applies to a compounded tirzepatide tablet or injection, from Medvi or anyone else selling one.

Zepbound has two real paths to a lower number. If your commercial insurance covers Zepbound, Eli Lilly's savings card can bring a fill down to as little as $25 a month, capped around $1,300 a year. And starting July 1, 2026, a CMS pilot called the Medicare GLP-1 Bridge program lets eligible Medicare Part D members get the Zepbound KwikPen specifically — not the single-dose vial — for a flat $50 monthly copay, if they meet a BMI and qualifying-condition threshold. Neither route exists for a compounded product, Medvi's included, which is worth weighing seriously if you already have coverage that might apply.

Medvi or Zepbound — which fits your situation?

• Cost is the binding constraint, and compounded doesn't worry you → Medvi's discounted first month is the lower entry price. Budget for the ~$399–$499 ongoing range before you commit, and get your specific dose's price in writing.
• You have commercial insurance, or Medicare plus a qualifying BMI → Zepbound only. Neither the savings card nor the new Medicare Bridge program applies to anything Medvi sells.
• You're needle-averse above everything else → Medvi's oral tablet is the only pill in this comparison, but it's also the format here with no published absorption data — a fair trade-off to weigh, not a settled answer.
• You're already juggling other health subscriptions — HRT, a primary care membership — and trust matters as much as price → Zepbound's LillyDirect pathway comes with no warning letter, no compounding-pharmacy question mark, and a company you already know by name.
• You want the wider compounded-tirzepatide landscape, not just Medvi → see tirzepatide vs. Zepbound for more named providers, or the Henry Meds review for one of the other companies selling a compounded oral tirzepatide tablet.